PetVivo Signs Exclusive Sales and Marketing Agreement with VetStem for PrecisePRP® Canine and Equine Products
PetVivo Holdings (OTCQB: PETV) has secured an Exclusive License and Supply Agreement with VetStem to commercialize PrecisePRP®, an innovative off-the-shelf platelet-rich plasma product for dogs and horses. This first-in-class product eliminates the need for blood draws or centrifugation, providing veterinarians with a consistent dose of 4 billion platelets per vial at 500,000 platelets per microliter.
The product undergoes rigorous safety screening according to FDA CVM Guidance 254, including infectious disease screening and blood type testing. Two randomized placebo-controlled safety studies revealed no treatment-related adverse events. PrecisePRP® will complement PetVivo's existing Spryng™ with OsteoCushion™ technology, reinforcing the company's position in veterinary medical devices and regenerative medicine.
PetVivo Holdings (OTCQB: PETV) ha ottenuto un contratto di licenza esclusiva e fornitura con VetStem per commercializzare PrecisePRP®, un innovativo prodotto di plasma ricco di piastrine pronto all'uso per cani e cavalli. Questo prodotto di prima classe elimina la necessità di prelievi di sangue o centrifugazione, fornendo ai veterinari una dose costante di 4 miliardi di piastrine per fiala a 500.000 piastrine per microlitro.
Il prodotto subisce rigorosi controlli di sicurezza secondo le linee guida FDA CVM 254, inclusi screening per malattie infettive e test del gruppo sanguigno. Due studi randomizzati controllati con placebo hanno rivelato nessun evento avverso correlato al trattamento. PrecisePRP® completerà l'attuale tecnologia Spryng™ con OsteoCushion™ di PetVivo, rafforzando la posizione dell'azienda nei dispositivi medici veterinari e nella medicina rigenerativa.
PetVivo Holdings (OTCQB: PETV) ha obtenido un acuerdo de licencia exclusiva y suministro con VetStem para comercializar PrecisePRP®, un innovador producto de plasma rico en plaquetas listo para usar para perros y caballos. Este producto de primera clase elimina la necesidad de extracciones de sangre o centrifugación, proporcionando a los veterinarios una dosis constante de 4 mil millones de plaquetas por vial a 500,000 plaquetas por microlitro.
El producto pasa por rigurosas pruebas de seguridad de acuerdo con la guía FDA CVM 254, incluyendo pruebas de enfermedades infecciosas y de tipo de sangre. Dos estudios aleatorizados controlados con placebo no revelaron eventos adversos relacionados con el tratamiento. PrecisePRP® complementará la tecnología Spryng™ con OsteoCushion™ existente de PetVivo, reforzando la posición de la empresa en dispositivos médicos veterinarios y medicina regenerativa.
PetVivo Holdings (OTCQB: PETV)는 VetStem과 독점 라이센스 및 공급 계약을 체결하여 개와 말을 위한 혁신적인 기성 혈소판 풍부 혈장 제품인 PrecisePRP®를 상용화하였습니다. 이 최초의 제품은 혈액 채취나 원심분리의 필요성을 없애며, 수의사에게 미세리터당 500,000개의 혈소판으로 4억 개의 혈소판이 담긴 일관된 용량을 제공합니다.
이 제품은 FDA CVM 가이드라인 254에 따라 감염병 검사 및 혈액형 검사 등 철저한 안전성 검사를 거칩니다. 두 개의 무작위 위약 대조 안전성 연구에서 치료와 관련된 부작용은 발견되지 않았습니다. PrecisePRP®는 PetVivo의 기존 Spryng™과 OsteoCushion™ 기술을 보완하여 수의학 의료 기기 및 재생 의학 분야에서 회사의 입지를 강화할 것입니다.
PetVivo Holdings (OTCQB: PETV) a obtenu un accord de licence exclusive et de fourniture avec VetStem pour commercialiser PrecisePRP®, un produit innovant de plasma riche en plaquettes prêt à l'emploi pour les chiens et les chevaux. Ce produit de première classe élimine le besoin de prélèvements sanguins ou de centrifugation, fournissant aux vétérinaires une dose constante de 4 milliards de plaquettes par flacon à 500 000 plaquettes par microlitre.
Le produit subit des contrôles de sécurité rigoureux conformément aux directives de la FDA CVM 254, y compris des tests de maladies infectieuses et des tests de groupe sanguin. Deux études de sécurité randomisées contrôlées par placebo n'ont révélé aucun événement indésirable lié au traitement. PrecisePRP® viendra compléter la technologie existante de PetVivo, Spryng™ avec OsteoCushion™, renforçant ainsi la position de l'entreprise dans les dispositifs médicaux vétérinaires et la médecine régénérative.
PetVivo Holdings (OTCQB: PETV) hat einen exklusiven Lizenz- und Liefervertrag mit VetStem gesichert, um PrecisePRP®, ein innovatives Fertigprodukt mit plättchenreichem Plasma für Hunde und Pferde, zu vermarkten. Dieses Produkt der ersten Klasse beseitigt die Notwendigkeit von Blutentnahmen oder Zentrifugationen und bietet Tierärzten eine konstante Dosis von 4 Milliarden Thrombozyten pro Fläschchen bei 500.000 Thrombozyten pro Mikroliter.
Das Produkt durchläuft strenge Sicherheitsprüfungen gemäß den FDA CVM Richtlinien 254, einschließlich Tests auf Infektionskrankheiten und Blutgruppentests. Zwei randomisierte, placebo-kontrollierte Sicherheitsstudien zeigten keine behandlungsbezogenen unerwünschten Ereignisse. PrecisePRP® wird die bestehende Technologie Spryng™ mit OsteoCushion™ von PetVivo ergänzen und die Position des Unternehmens im Bereich der veterinärmedizinischen Geräte und der regenerativen Medizin stärken.
- Secured exclusive commercialization rights for PrecisePRP®, expanding product portfolio
- Product offers consistent dosage and eliminates need for blood draws/processing
- Successfully completed FDA-requested safety studies with no adverse events
- Strengthens market position in veterinary medical devices and regenerative medicine
- None.
MINNEAPOLIS, MN, Feb. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW), a leader in innovative veterinary medical solutions, has entered into an Exclusive License and Supply Agreement with VetStem, Inc. to commercialize VetStem’s innovative allogeneic orthobiologic products, PrecisePRP® canine and PrecisePRP® equine.
PrecisePRP® is a first-in-class off-the-shelf platelet-rich plasma (PRP) product designed for use by veterinarians. It is a leucoreduced, allogeneic, pooled, freeze-dried PRP intended to provide a species-specific source of concentrated platelets in plasma for intra-articular administration in dogs and horses. Unlike any PRP mechanical kits currently on the market. PrecisePRP™ does not require a blood draw or centrifugation making it a truly off-the-shelf product that is easy and convenient. Perhaps more important is the uniformity and consistency that PrecisePRP® guarantees. Each vial of PrecisePRP® contains a consistent dose of 4 billion platelets per vial at a concentration of 500,000 platelets per microliter and is leucoreduced with less than 1500 white blood cells per microliter.
To significantly minimize safety risks, all dog and horse donors are screened according to the FDA CVM Guidance 254. Along with infectious disease screening, donors are tested for blood type and plasma antibody to red blood cells, providing a low risk of transfusion reaction. At the request of the FDA, two randomized placebo-controlled safety studies were conducted in dogs and horses. There were no treatment-related adverse events reported in dogs or horses after treatment with PrecisePRP®.
“This is a game changer for veterinarians and their ability to treat their patients with PRP”, said Mike Eldred, PetVivo Board Member. “This innovative, and FDA reviewed product, will be a great addition to Spryng™ with OsteoCushion™ technology, and supports our strategy to be the leader in veterinary medical devices and regenerative medicine.”
“PetVivo is an innovation-driven veterinary company with a passionate vision to bring regenerative medicine to the practicing veterinarian. Their approach to delivering practical solutions to everyday clinical challenges is what convinced us to award them an exclusive commercialization contract for our flagship PrecisePRP® products” said VetStem’s CEO Dr. Bob Harman.
Spryng® with OsteoCushion® Technology. Spryng is an intra-articular injectable veterinary medical device composed of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
About PetVivo
PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW) is a biomedical device company focused on the manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for companion animals. The company employs a strategy of adapting human therapies for companion animals, enabling a more efficient path to market. PetVivo’s flagship product, Spryng™ with OsteoCushion™ Technology, is a veterinarian-administered injectable designed to manage joint-related afflictions, including osteoarthritis, in cats, dogs, and horses. With a robust pipeline of products and a portfolio of 21 patents, PetVivo is dedicated to improving the health and quality of life of companion animals. For more information about PetVivo and its groundbreaking Spryng with OsteoCushion Technology, email info1@petvivo.com or visit www.petvivo.com or www.sprynghealth.com.
About VetStem
VetStem, Inc. is a veterinarian-led company established in 2002 to bring regenerative medicine to the veterinary profession. Based near San Diego, California, this privately held biopharmaceutical enterprise offers veterinarians a range of regenerative modalities, including autologous stem cell processing from patients’ own fat tissue. With over 15 years of expertise and thousands of treatments for joint, tendon, and ligament issues, VetStem has made regenerative medicine a therapeutic reality. The VetStem team is dedicated to developing clinically practical and affordable solutions that harness the natural restorative abilities of living organisms. In addition to its own patents, VetStem holds exclusive global veterinary licenses to a significant portfolio of patents in regenerative medicine and is in the late stages of approval of additional regenerative medicine solutions for the veterinarian. For additional information visit www.vetstem.com.
Disclosure Information
PetVivo uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the company’s Investor Relations website, in addition to following the company’s press releases, SEC filings, public conference calls, presentations and webcasts.
Forward-Looking commercial Statements
The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024, and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216
Attachment
FAQ
What is the platelet concentration in each vial of PrecisePRP® (PETV)?
How does PrecisePRP® differ from traditional PRP products in veterinary medicine?
What safety testing has been completed for PetVivo's PrecisePRP®?
How does the VetStem agreement impact PETV's market position?
